Figure 6. Subgroup analysis of incidences of pneumonitis in cancer patients receiving nivolumab or pembrolizumab.
Summary incidences of all-grade (A) and high-grade (B) pneumonitis in patients receiving either nivolumab or pembrolizumab were calculated with random effects model and fixed effects model, respectively. Size of squares was directly proportional to amount of information available.